US FDA’s Current Technical Standards Not A Good Fit For Real-World Data, Stakeholders Say
Executive Summary
The agency’s existing technical standards are better-suited to clinical trial data, and mapping RWD to these formats will result in the loss of granularity and introduce new opportunities for human error, pharmaceutical industry representatives and data companies say in comments on a draft guidance.
You may also be interested in...
Real-World Data: FDA Expounds On Use Of Registries, Challenges In Standardization
Final guidance on assessing registries notes responsibility of sponsors to ensure reliability of data from other organizations and reduce loss of participants to follow-up, while final guidance on data standards for RWD acknowledges sponsors may have limited access to a study’s data sources.
Real-World Evidence: US FDA Urged To Leverage Prior Validation Work and Regulatory Experience
In comments on FDA guidance on electronic health records and medical claims, Duke-Margolis Center suggests a certification process for validated datasets, while data companies request the agency do more to publicize the experience to date with RWE in regulatory submissions.
Real-World Evidence: ‘Labor-Intensive’ Data Standardization May Be Required By US FDA
New draft guidance offers recommendations for translating real-world data from claims or EHR sources to meet FDA data requirements.